Publications: Neisseria meningitidis

2000 to Present:

  • MacNeil JR, Blain AE, Wang X, Cohn AC. Current epidemiology and trends in meningococcal disease — United States, 1996–2015External. Clin Infect Dis. 2018;66(8):1276–81
  • Cohn AC, MacNeil JR, Harrison LH, et al. Effectiveness and duration of protection of one dose of a meningococcal conjugate vaccine. Pediatrics. 2017;139(2). pii: e20162193.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2016 Cdc-pdf[1 page].
  • Harris CM, Wu HM, Li J, et al. Meningococcal disease in patients with human immunodefiency virus infection: A review of cases reported through active surveillance in the United States, 2000–2008. Open Forum Infect Dis. 2016;3(4):ofw226.
  • Blain A, Mandal S, Wu H, et al. Penicillin use in meningococcal disease management, Active Bacterial Core surveillance sites, 2009. Open Forum Infect Dis. 2016;3(3):ofw152.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2015 Cdc-pdf[1 page].
  • Harcourt BH, Anderson RD, Wu HM, et al. Population-based surveillance of Neisseria meningitidis antimicrobial resistance in the United States. Open Forum Infect Dis. 2015;2(3):ofv117.
  • MacNeil JR, Bennett N, Farley MM, et al. Epidemiology of infant meningococcal disease in the United States, 2006-2012. Pediatrics. 2015;135(2):e305-11.
  • Wang X, Shutt KA, Vuong JT, et al. Changes in the population structure of invasive Neisseria meningitidis in the United States after quadrivalent meningococcal conjugate vaccine licensure. J Infect Dis. 2015;211(12):1887-94.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2014Cdc-pdf.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2013Cdc-pdf[1 page].
  • Harrison LH, Shutt KA, Arnold KE, et al. Meningococcal carriage among Georgia and Maryland high school students. J Infect Dis. 2014;211(11):1761-8.
  • Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013;62(RR-2).
  • MacNeil JR, Rubin L, McNamara L, Briere EC, Clark TA, Cohn AC. Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices, 2013. MMWR Morb Mortal Wkly Rep. 2014;63(24):527-30.
  • Wiringa AE, Shutt KA, Marsh JW, et al. Geotemporal analysis of Neisseria meningitidis clones in the United States: 2000-2005. PLoS One. 2013;8(12):e82048.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2012Cdc-pdf[2 pages].
  • Centers for Disease Control and Prevention. Comparison of meningococcal disease surveillance systems – United States, 2005-2008. MMWR Morb Mortal Wkly Rep. 2012;61(17):306-08.
  • Krauland MG, Dunning Hotopp JC, Riley DR, et al. Whole genome sequencing to investigate the emergence of clonal complex 23 Neisseria meningitidis serogroup Y disease in the United States. PLoS One. 2012;7(4):e35699.
  • Wang X, Theodore MJ, Mair R, et al. Clinical validation of multiplex real-time PCR assays for detection of bacterial meningitis pathogens. J Clin Microbiol. 2012;50:702-708.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2011Cdc-pdf[1 page].
  • Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. MMWR Morb Mortal Wkly Rep. 2011;60(40):1391-2.
  • Centers for Disease Control and Prevention. Updated recommendations for use of meningococcal conjugate vaccines – Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2011;60(3):72-6.
  • Katz LS, Sharma NV, Harcourt BH, et al. Using single nucleotide polymorphisms to discriminate disease associated from carried genomes of Neisseria meningitidis. J Bacteriology. 2011;193:3633-41.
  • Katz LS, Humphrey JC, Conley AB, et al. Neisseria base: A comparative genomics database for Neisseria meningitidis. Database (Oxford). 2011;2011:bar035.
  • MacNeil JR, Cohn AC, Zell ER, et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J. 2011;30(6):451-5.
  • Thomas, JD, Hatcher CP, Satterfield DA, et al. sodC-based real-time PCR for detection of Neisseria meningitidis. PLoS ONE. 2011;6(5):e19361.
  • Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29-30):4739-44.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2010.
  • Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: Implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184-91.
  • Harrison LH, Shutt KA, Schmink SE, et al. Population structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era, United States, 2000-2005. J Infect Dis. 2010;201(8):1208-24.
  • Kislyuk AO, Katz LS, Agrawal S, et al. A computational genomics pipeline for microbial sequencing projects. Bioinformatics. 2010;26:1819-26.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2009.
  • Wu HM, Harcourt BH, Wei S, et al. Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med. 2009;360:886-892.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2008.
  • Centers for Disease Control and Prevention. Report from ACIP: Decision not to recommend routine vaccination of all children aged 2-10 years with MCV4. MMWR Morb Mortal Wkly Rep. 2008;57(17):462-5.
  • Harrison LH, Kreiner CJ, Shutt KA, et al. Risk factors for meningococcal disease in students in grades 9-12. Ped Infect Dis J. 2008;27:193-199.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2007.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2006.
  • Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization – International Meeting Report, Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine. 2006;24:5093-107.
  • Harrison LH, Jolley KA, Shutt KA, et al. Antigenic shift and the incidence of meningococcal infection. J Infect Dis. 2006;193(9):1266-74.
  • Harrison LH, Maiden MC. Reply to Tsang et al. J Infect Dis. 2006;194:1792-3.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2005.
  • Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2005;54(RR-7):1-21.
  • Dull P, Abdelwahab J, Sacchi C, et al. Serogroup W-135 Neisseria meningitidis carriage among U.S. travelers to the 2001 Hajj. J Infect Dis. 2005;191:33-9.
  • Rainbow J, Cebelinski E, Bartkus J, Glennen A, Boxrud D, Lynfield R. Rifampin-resistant meningococcal disease. Emerg Infect Dis. 2005;11(6):977-9.
  • Sejvar JJ, Johnson D, Popovic T, et al. Assessing the risk of laboratory-acquired meningococcal disease in the United States, 1996-2000. J Clin Microbiol. 2005;24:4811-4.
  • Shepard CW, Ortega-Sanchez IR, Scott RD, Rosenstein NE, ABCs Team. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics. 2005;115(5):1220-32.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2004.
  • McEllistrem MC, Kolano JA, Pass MA, et al. Epidemiologic trends and genotypes causing meningococcal disease, Maryland. Emerg Infect Dis. 2004;10:451-6.
  • Mothershed EA, Sacchi CT, Whitney AM, et al. Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis. J Clin Microbiol. 2004;42:320-8.
  • Raghunathan PL, Bernhardt SA, Rosenstein NE. Opportunities for control of meningococcal disease in the United States. Ann Rev Med. 2004;55:333-53.
  • Zimmer S, Stephens DS. Meningococcal conjugate vaccine. Expert Opin Pharmacother. 2004;4:855-63.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2003.
  • Dolan-Livengood JM, Miller YK, Kahler CM, Reeves M, Ajello G, Stephens DS. Genetic basis for nongroublable Neisseria meningitidis. J Jnfect Dis. 2003;187:1616-28.
  • Shepard CW, Rosenstein NE, Fischer M, and the Active Bacterial Core Surveillance Team. Neonatal meningococcal disease in the United States, 1990-1999. Pediatr Infect Dis J. 2003;22:418-22.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2002.
  • Kellerman S, McCombs K, Ray M, et al. Genotype-specific carriage of Neisseria meningitidis in Georgia counties with hyper- and hyposporadic rates of meningococcal disease. J Infect Dis. 2002;186:40-8.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2001.
  • Finn R, Groves C, Coe M, Pass M, Harrison LH. A cluster of serogroup C meningococcal disease associated with attendance at a party. South Med J. 2001;94(12):1192-4.
  • Harrison LH, Pass MA, Mendelsohn AB, et al. Invasive meningococcal disease in adolescents and young adults. 2001;286:694-9.
  • Lingappa JR, Rosenstein N, Zell ER, et al. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Vaccine. 2001;19(31):4566-75.
  • Popovic T, Schmink S, Rosenstein NA, et al. Evaluation of pulsed-field gel electrophoresis in epidemiological investigations of meningococcal disease outbreaks caused by Neisseria meningitidis serogroup C. J Clin Microbiol. 2001;39(1):75-85.
  • Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med. 2001;344:1378-88.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2000.
  • Rosenstein NE, Stocker SA, Popovic T, Tenover FC, Perkins BA, and the Active Bacterial Core Surveillance Team. Antimicrobial resistance of Neisseria meningitidis in the United States, 1997. Clin Infect Dis. 2000;30:212-3.
  • Sacchi CT, Whitney AM, Popovic T, et al. Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998. J Infect Dis. 2000;182:1169-76.
  • Tondella M, Popovic T, Rosenstein N, Lake D, Carlone G, Perkins B. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. J Clin Microbiol. 2000;38:3323-8.

 Top of Page

1995-1999:

  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 1999.
  • Diermayer M, Hedberg K, Hoesly F, et al. Epidemic serogroup B meningococcal disease in Oregon: The evolving epidemiology of the ET-5 strain. JAMA. 1999;281(16):1493-7.
  • Harrison LH, Dwyer DM, Maples CT, Billmann L. The risk of meningococcal infection in college students. JAMA. 1999;281:1906-10.
  • Rosenstein NE, Perkins BA, Stephens D, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis. 1999;180:1894-901.
  • Yusuf HR, Rochat RW, Baughman WS, et al. Maternal cigarette smoking and invasive meningococcal disease: A cohort study among young children in metropolitan Atlanta, 1989-1996. Am J Public Health. 1999;89:712-7.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 1998.
  • Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 1997.
  • Centers for Disease Control and Prevention. Control and prevention of meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1997;46(No. RR-5):1-10.
  • Centers for Disease Control and Prevention. Control and prevention of serogroup C meningococcal disease: Evaluation and management of suspected outbreaks: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 1997;46(No. RR-5):13-21.
  • Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J. 1997;16:979-83.
  • Raymond NJ, Reeves M, Ajello G, et al. Molecular epidemiology of sporadic (endemic) serogroup C meningococcal disease. J Infect Dis. 1997;176:1277-84.
  • Swartley JS, Marfin AA, Edupuganti S, et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci. 1997;94:271-6.
  • Zangwill K, Schuchat A, Riedo FX, et al. School-based clusters of meningococcal disease in the United States: Descriptive epidemiology and a case-control analysis. JAMA. 1997;277:389-95.
  • Centers for Disease Control and Prevention. Serogroup Y meningococcal disease — Illinois, Connecticut, and selected areas, United States, 1989-1996. MMWR Morb Mortal Wkly Rep. 1996;45:1010-13.
  • Centers for Disease Control and Prevention. Serogroup B meningococcal disease — Oregon 1994. MMWR Morb Mortal Wkly Rep. 1995;44:121-4.
  • Jackson LA, Schuchat A, Gorsky RD, Wenger JD. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis. Am J Public Health. 1995;85:843-5.
  • Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States: An emerging threat. JAMA. 1995;273:383-9.
  • Reeves MW, Perkins BA, Diermayer M, Wenger JD. Epidemic-associated Neisseria meningitidis detected by multilocus enzyme electrophoresis. Emerg Infect Dis. 1995;1:53-4.
  • Stephens DS, Hajjeh RA, Baughman WS, Harvey CH, Wenger JD, Farley MM. Sporadic meningococcal disease in adults: Results of a 5-year population-based study. Ann Intern Med. 1995;123:937-40.

 Top of Page

1988-1994:

  • Jackson LA, Tenover FC, Baker C, et al. Prevalence of Neisseria meningitidis relatively resistant to penicillin in the United States, 1991. J Infect Dis. 1994;169:338-41.
  • Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected counties, United States, 1989-1991. MMWR Morb Mortal Wkly Rep. 1993;42:21-30.
  • Pinner RW, Gellin BG, Bibb WF, et al. Meningococcal disease in the United States – 1986. J Infect Dis. 1991;164:368-74.

 Top of Page